Search

Your search keyword '"Memtsoudis, Stavros G."' showing total 693 results
Start Over Author "Memtsoudis, Stavros G." Publication Year Range Last 10 years Language english
693 results on '"Memtsoudis, Stavros G."'

7. Effectiveness of oral versus intravenous tranexamic acid in primary total hip and knee arthroplasty: a randomised, non-inferiority trial

Author

DeFrancesco, Christopher J., Reichel, Julia F., Gbaje, Ejiro, Popovic, Marko, Freeman, Carrie, Wong, Marisa, DeMeo, Danya, Liu, Jiabin, Gonzalez Della Valle, Alejandro, Ranawat, Amar, Cross, Michael, Sculco, Peter K., Haskins, Stephen, Kim, David, Maalouf, Daniel, Kirksey, Meghan, Jules-Elysee, Kethy, Soffin, Ellen M., Kumar, Kanupriya, Beathe, Jonathan, Figgie, Mark, Inglis, Allan, Jr., Garvin, Sean, Alexiades, Michael, DelPizzo, Kathryn, Russell, Linda A., Sideris, Alexandra, Saleh, Jawad, Zhong, Haoyan, and Memtsoudis, Stavros G.

Published
2023
Full Text
View/download PDF

24. Does the impact of peripheral nerve blocks vary by age and comorbidity subgroups? A nationwide population-based study.

Author

Haoyan Zhong, Poeran, Jashvant, Cozowicz, Crispiana, Athanassoglou, Vassilis, Illescas, Alex, Memtsoudis, Stavros G., and Jiabin Liu

Abstract

Introduction A large body of literature suggests that peripheral nerve blockade (PNB) is associated with improved perioperative outcomes in total hip and knee joint arthroplasty patients. However, it is unclear to what extent this association exists across patient subgroups based on age and health status. Methods Patients who underwent total joint arthroplasty were identified from the Premier Healthcare database (2006-2019). Mixed-effects models were applied to assess the relationship between exposure of interest (PNB use on the day of surgery) and various outcomes (postoperative respiratory complications, acute renal failure, delirium, intensive care unit admission, prolonged length of stay, and high opioid consumption) across multiple subgroups stratified by patient age and pre-existing comorbidities. Results PNB use and outcome association varies based on the patient's health and age characteristics. For adults and older adults with excellent or fair, there was a decrease in the likelihood of respiratory complication with the use of PNB (OR: 0.92, 95% CI 0.86 to 0.98; OR: 0.88, 95% CI 0.81 to 0.95; OR: 0.94, 95% CI 0.89 to 0.99, respectively). Peripheral nerve blocks were also associated with a reduction in the odds of high opioid consumption across all categories except adult patients in poor health. Conclusion PNB use is associated with beneficial effects more commonly observed among patients with a lower comorbidity burden, without a clear pattern of association with patient age. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Anaesthetic care of patients undergoing primary hip and knee arthroplasty: consensus recommendations from the International Consensus on Anaesthesia-Related Outcomes after Surgery group (ICAROS) based on a systematic review and meta-analysis

Author

Memtsoudis, Stavros G., Cozowicz, Crispiana, Bekeris, Janis, Bekere, Dace, Liu, Jiabin, Soffin, Ellen M., Mariano, Edward R., Johnson, Rebecca L., Hargett, Mary J., Lee, Bradley H., Wendel, Pamela, Brouillette, Mark, Go, George, Kim, Sang J., Baaklini, Lila, Wetmore, Douglas, Hong, Genewoo, Goto, Rie, Jivanelli, Bridget, Argyra, Eriphyli, Barrington, Michael J., Borgeat, Alain, De Andres, Jose, Elkassabany, Nabil M., Gautier, Philippe E., Gerner, Peter, Gonzalez Della Valle, Alejandro, Goytizolo, Enrique, Kessler, Paul, Kopp, Sandra L., Lavand’Homme, Patricia, MacLean, Catherine H., Mantilla, Carlos B., MacIsaac, Daniel, McLawhorn, Alexander, Neal, Joseph M., Parks, Michael, Parvizi, Javad, Pichler, Lukas, Poeran, Jashvant, Poultsides, Lazaros A., Sites, Brian D., Stundner, Otto, Sun, Eric C., Viscusi, Eugene R., Votta-Velis, Effrossyni G., Wu, Christopher L., Ya Deau, Jacques T., and Sharrock, Nigel E.

Published
2019
Full Text
View/download PDF

38. Tranexamic Acid Use in Total Joint Arthroplasty: The Clinical Practice Guidelines Endorsed by the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society

Author

Fillingham, Yale A., Ramkumar, Dipak B., Jevsevar, David S., Yates, Adolph J., Bini, Stefano A., Clarke, Henry D., Schemitsch, Emil, Johnson, Rebecca L., Memtsoudis, Stavros G., Sayeed, Siraj A., Sah, Alexander P., and Della Valle, Craig J.

Published
2018
Full Text
View/download PDF

43. Trends of liposomal bupivacaine utilization in major lower extremity total joint arthroplasty in the USA: a population-based study.

Author

Stundner, Ottokar, Hoerner, Elisabeth, Haoyan Zhong, Poeran, Jashvant, Jiabin Liu, Illescas, Alex, and Memtsoudis, Stavros G.

Abstract

Introduction Liposomal bupivacaine has been marketed for the achievement of long-acting local or regional anesthesia after major lower extremity total joint arthroplasty. However, it is comparatively expensive and controversy remains regarding its ability to decrease healthcare costs. With mounting evidence suggesting non-superiority in efficacy, compared with plain bupivacaine, we sought to investigate trends in liposomal bupivacaine use and identify changes in practice. Methods We identified adult patients from the Premier Healthcare Database who underwent elective total joint arthroplasty between 2012 and 2021. Prevalence and trends of liposomal bupivacaine utilization were compared on the individual patient and hospital levels. Log-rank tests were performed to assess the influence of location, teaching status, or hospital size on time to hospital-level liposomal bupivacaine termination. Results Among 103,165 total joint arthroplasty cases, liposomal bupivacaine use increased between 2012 and 2015 (from 0.4% to 22.8%) and decreased by approximately 1%-3% annually thereafter (15.7% in 2021). Liposomal bupivacaine was ever used in approximately 60% of hospitals. Hospital-level initiation of liposomal bupivacaine use peaked in 2014 and decreased thereafter (from 32.8% in 2013 to 4.3% in 2021), while termination rates increased (from 1.4% in 2014 to 9.9% in 2019). Non-teaching hospitals and those located in the South and West regions were more likely to retain liposomal bupivacaine longer than teaching or Midwest/Northeast hospitals, respectively (p=0.023 and p=0.014). Discussion Liposomal bupivacaine use peaked around 2015 and has been declining thereafter on individual patient and hospital levels. How these trends correlate with health outcomes and expenditures would be a strategic target for future research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Surgical opioid-avoidance protocol: a postoperative pharmacological multimodal analgesic intervention in diverse patient populations.

Author

Votta-Velis, Gina, Daviglus, Martha L., Borgeat, Alain, Beckmann, Katharina, Ta, Andrew Q., Parker, John L., Kravets, Sasha, Garcia, Olga L., Pirzada, Amber, Gastala, Nicole, Valle, Valentina, Benken, Jamie J., Campara, Maya, Aguiluz, Gabriela, Memtsoudis, Stavros G., Giulianotti, Pier C., and Benedetti, Enrico

Abstract

Introduction This study evaluated the effect of a surgical opioid-avoidance protocol (SOAP) on postoperative pain scores. The primary goal was to demonstrate that the SOAP was as effective as the pre-existing non-SOAP (without opioid restriction) protocol by measuring postoperative pain in a diverse, opioid-naive patient population undergoing inpatient surgery across multiple surgical services. Methods This prospective cohort study was divided into SOAP and non-SOAP groups based on surgery date. The non-SOAP group had no opioid restrictions (n=382), while the SOAP group (n=449) used a rigorous, opioid-avoidance order set with patient and staff education regarding multimodal analgesia. A non-inferiority analysis assessed the SOAP impact on postoperative pain scores. Results Postoperative pain scores in the SOAP group compared with the non-SOAP group were non-inferior (95% CI: -0.58, 0.10; non-inferiority margin=-1). The SOAP group consumed fewer postoperative opioids (median=0.67 (IQR=15) vs 8.17 morphine milliequivalents (MMEs) (IQR=40.33); p<0.01) and had fewer discharge prescription opioids (median=0 (IQR=60) vs 86.4 MMEs (IQR=140.4); p<0.01). Discussion The SOAP was as effective as the non-SOAP group in postoperative pain scores across a diverse patient population and associated with lower postoperative opioid consumption and discharge prescription opioids. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results